Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk

Mary Beth Terry, Mary B. Daly, Kelly Anne Phillips, Xinran Ma, Nur Zeinomar, Nicole Leoce, Gillian S. Dite, Robert J. MacInnis, Wendy K. Chung, Julia A. Knight, Melissa C. Southey, Roger L. Milne, David Goldgar, Graham G. Giles, Prue C. Weideman, Gord Glendon, Richard Buchsbaum, Irene L. Andrulis, Esther M. John, Saundra S. BuysJohn L. Hopper

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)

Abstract

There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI]=0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR=0.68, 95% CI=0.32 to 1.47, HR=0.94, 95% CI=0.70 to 1.26, and HR=1.10, 95% CI=0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.

Original languageEnglish
Pages (from-to)331-334
Number of pages4
JournalJournal of the National Cancer Institute
Volume111
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019
Externally publishedYes

Cite this